🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparision of Hydrodilatation Results at Different Volumes in Adhesive Capsulitis by Phases.

RecruitingNAAges 30 Years - 70 YearsAllJavier Muñoz Paz
NCT06939530 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Adhesive capsulitis (AC) causes a global limitation of active and passive range of motion (ROM) in the shoulder, with or without pain, and no other radiographic findings. The natural process is self-limiting, evolving in three or four phases. It is common in women around 50 years of age. Diagnosis is based on clinical symptoms, with imaging tests being nonspecific. Treatment options include physical therapy (PT), intra-articular corticosteroid injections, suprascapular nerve block (SSNB), and hydrodilatation (HD). The latter is useful for expanding and reducing inflammation of the joint capsule through insufflation with saline solution, anesthetics, and corticosteroids. Objectives: To determine whether patients with AC, stratified by phase, who receive high-volume HD therapy achieve better outcomes in the Shoulder Pain and Disability Index (SPADI), Analgesic Analogue Scale (VAS), and RO

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Ages between 30 and 70 years. * Limited ROM, both active and passive, in two planes. * Shoulder pain lasting more than 3 months. Exclusion Criteria: * Lidocaine + trial with improved ROM. * Conditions that preclude treatment (active cancer, tissue infection, oral anticoagulant use, cardiac arrhythmias, etc.) * Previously receiving HD treatment in less than 1 year. * Stage 0 or 3 AC. * Non-adherence to the PT program, with attendance failures exceeding 20%. * Presence of conditions that can cause similar symptoms, such as acromioclavicular osteoarthritis, labral injury, massive rotator cuff tear, or rheumatic diseases. * Intra-articular corticosteroid injection in less than 2 months. * Technique failure.
💊

What it tests

  • Hydrodilatation (20 ml)
  • Hydrodilatation (40 ml)
📍

Where

1 site
Hospital Universitario Reina Sofia
Córdoba, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy